|
1）後藤信哉．抗血栓療法ハンドブック．東京: 中外医学社; 2011
|
|
|
|
|
2）後藤信哉．浅田祐士郎．血栓症-やさしく，くわしく，わかりやすく．東京: 南江堂; 2006
|
|
|
|
|
|
3）後藤信哉．そこが知りたい抗血栓療法．Vol 1. 東京: メディカルレビュー社; 2011
|
|
|
|
|
|
4）Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012; 366: 54-63
|
|
|
|
|
5）Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011; 364: 1144-53
|
|
|
|
|
|
6）Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|
|
7）Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92
|
|
|
|
|
|
8）Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91
|
|
|
|
|
|
9）Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008; 156: 855-63, 863. e8
|
|
|
|
|
|
10）Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50: 309-15
|
|
|
|
|
|
11）Atarashi H, Inoue H, Okumura K, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J. 2011; 75: 1328-33
|
|
|
|
|
12）Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke. 2008; 39: 1740-5
|
|
|
|
|
|
13）Goto S, Ikeda Y, Shimada K, et al. One-year cardiovascular event rates in Japanese outpati-ents with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ J. 2011; 75: 2598-604
|
|
|
|
|
|
14）Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012; 11: 503-11
|
|
|
|
|
|
15）Diener HC, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012; 11: 225-31
|
|
|
|
|
|
16）Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376: 975-83
|
|
|
|
|
|
17）Goto S. Monitoring of the effects of new-generation oral anticoagulants - what does it mean? Circ J. 2012; 76: 596-7
|
|
|
|
|
|
18）Suzuki S, Otsuka T, Sagara K, et al. Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. Circ J. 2012; 76: 755-7
|
|
|
|
|
|
19）Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107: 985-97
|
|
|
|
|
|
20）Tripodi A. Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? Thromb Haemost. 2011; 105: 735-6
|
|
|
|
|
|
21）Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60
|
|
|
|
|
|
22）Goto S, Chan Y, Wilson JC, et al; on behalf of the REACH Registry Investigators. Risk-factor profile, drug usage and cardiovascular events within a year in patients with and a high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asia regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia. 2011; 3: 93-8
|
|
|
|
|
|
23）Goto S, Hills G, Hu T, et al. How can we avoid a stroke crisis in the Asia-Pacific region? 1st ed. London: Chameleon Communications Inter-national; 2011
|
|
|
|
|
|
24）Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92
|
|
|
|
|